nystatin-a1 and Xerostomia

The salivary component of Sjögren's syndrome (SS) is defined as xerostomia (dry mouth). However, xerostomia is a common symptom associated with quantitative and qualitative changes in saliva, which are generally referred to as salivary hypofunction. This can be caused by various systemic diseases (including SS), anticholinergic effects of many drugs, psychological conditions, and physiological changes. Chronic salivary hypofunction is clinically significant because it can cause oral dysfunction, dental destruction, and mucosal infection. Evaluating patients complaining of xerostomia requires particular attention to their current medications and physical examination of the major salivary glands, teeth, and oral mucosa. Based on that information and the differential diagnosis of salivary hypofunction, appropriate tests can then be selected to develop a final diagnosis. Effective treatment of patients with chronic salivary hypofunction requires a combination of: (1) ongoing dental decay prevention and treatment supervised by their dentist; (2) salivary flow stimulation; (3) recognition and treatment of chronic oral candidiasis; (4) selective use of saliva substitutes; and (5) prescription drug review.

Topics: Antifungal Agents; Candidiasis, Oral; Diagnosis, Differential; Humans; Nystatin; Sjogren's Syndrome; Xerostomia

The aim of this study was to compare the effectiveness of denture microwave disinfection and antifungal therapy on treatment of denture stomatitis.. Sixty denture wearers with denture stomatitis (3 groups; n = 20 each), were treated with nystatin or denture microwave disinfection (1 or 3 times/wk) for 14 days. Mycologic samples from palates and dentures were quantified and identified with the use of Chromagar, and clinical photographs of palates were taken. Microbiologic and clinical data were analyzed with the use of a series of statistical tests (α = .05).. Both treatments similarly reduced clinical signs of denture stomatitis and growth on palates and dentures at days 14 and 30 (P > .05). At sequential appointments, the predominant species (P < .01) isolated was C. albicans (range 98%-53%), followed by C. glabrata (range 22%-12%) and C. tropicalis (range 25%-7%).. Microwave disinfection, at once per week for 2 treatments, was as effective as topical antifungal therapy for treating denture stomatitis.

Topics: Adult; Aged; Analysis of Variance; Antifungal Agents; Chi-Square Distribution; Denture, Complete; Disinfection; Female; Humans; Male; Microwaves; Middle Aged; Mycoses; Nystatin; Oral Hygiene; Smoking; Stomatitis, Denture; Treatment Outcome; Xerostomia

The efficacy of oral fluconazole versus nystatin was evaluated as a treatment modality for oral candidosis. Of the included patients (n = 60), two-thirds presented with an erythematous candidosis, and the others showed clinical signs compatible with a pseudomembranous candidosis. Predisposing factors were xerostomia (n = 18), HIV (n = 5), immunosuppression in conjunction with organ transplantation (n = 10), and wearing of dentures (n = 14). For the remaining patients no specific predisposing factors were found. One patient who was treated with nystatin was excluded owing to nausea that was related to the antifungal treatment. After 7 days of treatment with fluconazole (50 mg/day), the affected oral mucosa, assessed by the investigator, was cured or showed considerable improvement in 87% of the patients (n = 30). The corresponding figure for the nystatin group (n = 30), rinsing with 1 mL 4 times a day for 21 days, was 80%. Following treatment with fluconazole, 20 of 22 patients with symptoms at the start (91%) reported improvement. The comparable figures for the nystatin group were 10 of 12 patients (83%). Half of the patients in the nystatin group reported inconvenience from taking the medication (mean value = 25.9) compared with 23% of the patients in the fluconazole group (mean value = 6.6). Eight patients in the fluconazole group and 12 patients in the nystatin group exhibited a relapse within 6 months. These differences were not found to be statistically significant. The patients in the fluconazole group reported less inconvenience from taking the medication, a finding that may have clinical implications for compliance.

Topics: Administration, Oral; Adult; Aged; Antifungal Agents; Candidiasis, Oral; Capsules; Dentures; Erythema; Female; Fluconazole; Follow-Up Studies; HIV Infections; Humans; Immunosuppression Therapy; Male; Middle Aged; Mouth Mucosa; Mouthwashes; Nystatin; Organ Transplantation; Patient Compliance; Patient Satisfaction; Recurrence; Risk Factors; Xerostomia

Topics: Aged; Antifungal Agents; Candidiasis, Chronic Mucocutaneous; Dental Caries; Excipients; Humans; Male; Nystatin; Sucrose; Suspensions; Tracheal Diseases; Xerostomia

Topics: Amphotericin B; Antidepressive Agents; Candidiasis, Oral; Candidiasis, Vulvovaginal; Drug Therapy; Mental Disorders; Nystatin; Oral Manifestations; Toxicology; Tranquilizing Agents; Xerostomia